arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Voyager Therapeutics, Inc.

VYGR
$1.73 ▼ -0.15 (-8.24%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Voyager Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $101.5M
Dividend Yield —
Revenue Growth -49.5% ↗
Op. Margin -326.6% ↘
ROIC -67.3% ↘
FCF / Share $-2.30 ↘
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.37M
↓ -49.5% —
Net Income Profit after all expenses
$-119.72M
↓ -84.2% —
Operating Margin Operating profit as % of sales
-326.6%
↓ -213.7% 0th
FCF / Share Free cash flow per share
$-2.30
↓ -604.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↑
14
Cash Quality ↑
70

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 50 quarters